Orbus Therapeutics is a late-stage clinical company with a treatment for brain cancer. Orbus is conducting a phase 3 study using Eflornithine in recurrent Anaplastic Astrocytoma (“rAA”) patients. rAA is a devastating brain cancer with a median survival of a year or less. Currently there are no drugs approved for this condition.